A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, LONG-TERM SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA AT RISK OF CARDIOVASCULAR EVENTS

Registry ID

B1481020

Source registry

HEALTH_CANADA

Status

Closed

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

PFIZER CANADA INC

Start date

2014-07-04

Completion date

2016-09-08

Last update

2014-05-16

Conditions

• PRIMARY HYPERLIPIDEMIA
• MIXED DYSLIPIDEMIA

Related clinical trials

• A DOUBLE BLIND, RANDOMIZED, PLACEBO CONTROLLED, MULTICENTER STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY ON LDL-C OF EVOLOCUMAB (AMG 145) IN SUBJECTS WITH HIV AND WITH HYPERLIPIDEMIA AND/OR MIXED DYSLIPIDEMIN
• A 52 WEEK, PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPDEMIA OR MIXED DYSLIPIDEMIA AT RISK OF CARDIOVASCULAR EVENTS. SPIRE-LL: STUDIES OF PCSK9 INHIBITION AND THE REDUCTION OF VASCULAR EVENTS - LIPID LOWERING
• A PHASE 3 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY, SAFETY AND TOLERABILITY OF PF-04950615 IN SUBJECTS WITH PRIMARY HYPERLIPIDEMIA OR DYSLIPDEMIA AT RISK OF CARDIOVASCULAR EVENTS
• "A MULTICENTER, CONTROLLED, OPEN-LABEL EXTENSION (OLE) STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF AMG 145."

View on source registry